HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Snake venoms and coagulopathy.

Abstract
Snakebite affects around 2.5 million humans annually, with greater than 100,000 deaths. Coagulopathy is a significant cause of both morbidity and mortality in these patients, either directly, or indirectly. This paper reviews clinical aspects of snakebite coagulopathy, including types of coagulopathy (procoagulant, fibrinogen clotting, fibrinolytic, platelet-active, anticoagulant, thrombotic, haemorrhagic), diagnosis and treatment. Examples of clinical laboratory findings in selected types of snakebite coagulopathy are presented. Where available, antivenom is the most effective treatment, while standard treatments for other forms of coagulopathy, such as factor replacement therapy and heparin, are either ineffective or dangerous in snakebite coagulopathy, except in specific situations.
AuthorsJulian White
JournalToxicon : official journal of the International Society on Toxinology (Toxicon) Vol. 45 Issue 8 Pg. 951-67 (Jun 15 2005) ISSN: 0041-0101 [Print] England
PMID15922768 (Publication Type: Journal Article, Review)
Chemical References
  • Antivenins
  • Snake Venoms
  • Fibrinogen
Topics
  • Algorithms
  • Animals
  • Antivenins (therapeutic use)
  • Blood Coagulation (drug effects)
  • Blood Coagulation Disorders (chemically induced, diagnosis, therapy)
  • Blood Platelets (metabolism)
  • Fibrinogen (metabolism)
  • Models, Biological
  • Snake Bites (therapy)
  • Snake Venoms (metabolism, toxicity)
  • Snakes

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: